Author

Emma V. Casella

University of Brescia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alessandro FanzaniiD· 1 shared Daniel C. AnderssoniD· 1 shared Silvia CodenottiiD· 1 shared Stefano GastaldelloiD· 1 shared Volker Martin LauschkeiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

5 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessandro FanzaniORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintJan 15, 2025

Synthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs tumor growth and chemosensitizers embryonal and alveolar rhabdomyosarcoma cell lines.

Silvia Codenotti, Volker Martin Lauschke, Emma V. Casella…·Stefano Gastaldello

This study shows that TAK-981, a SUMO inhibitor targeting SAE1, reduces RMS cell growth and enhances chemotherapy effectiveness without increasing radiosensitivity.

DOI 10.1101/2025.01.15.633172

humanbulk RNA-seq

𝕏 PostBluesky